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Abstract 
Composites were first used clinically in the 1970s, these were based on carbon reinforced 
epoxy resin and although they progressed to successful clinical applications, none remained 
in use much beyond their initial clinical trials. The major problems were either the inability to 
shape the implant to fit the patient, or the method of manufacture being expensive and 
complex, finally these materials were “first generation” biomedical composites being 
bioinert. In the 1980s the second generation, that is bioactive composites, were developed 
and brought into clinical trial. As surgeons have been able to shape these implants to fit their 
patients the application of these materials has been more successful and being bioactive have 
lead to stronger bonds between the implant and the supporting bone, thus the implants has 
progressed to clinical use after their initial clinical trials. However, most of these could only 
be used in low load bearing applications. Since the early 2000s and the first edition of this 
book, the number of composite implants in clinical application and the loads to which they 
are exposed have both increased substantially. Improvements have come from applying 
engineering composites technologies to increase the mechanical properties and the use of 
bioactive components and the release of bioactive molecules to increase the bioactivity of the 
materials and devices. 
 
 
3.1 Introduction 
As has been discussed elsewhere this 
book, there are a variety of reasons to use 
composites in biomedical applications and 
a wide range of composites which have 
been developed. Briefly, the major reason 
for using composites is that mechanical 
properties can be tailored for the specific 
application so that that these properies 
closely match the stiffness of the natural 
tissue, preventing stress transfer effects, 
and can have strength in excess of the 
natural tissue being replaced. This 
rationale applies to a wide range of tissues, 
from soft load bearing tissues including 
tendons (Amis et al., 1984; De Santis et 
al., 2004) and the intervertebral disc 
(Ambrosio et al., 1998), and in hard 
tissues, that is bone replacement and 
augmentation (Bonfield et al., 1980; 1981) 
and finally in the replacement of 
multilayer structures such as surface 
defects in joints where both the articular 
cartilage and the underlying cancellous 
bone are replaced (Lynn et al., 2010; 
Harley et al., 2010a; 2010b). This 
matching of the mechanical properties can 
include duplication the non-linear 
behaviour of natural tissues and aims to 
optimise the load or stress transfer across 
the implant-tissue interface, thus reducing 
the risks associated with stress shielding of 
the natural tissue or stress concentrations 
at the interface. The second reason is that 
the biological properties of the composite 
also can be tailored to optimise the 
biological response to the presence of the 
implant thus a strong biological interface 
can be produced by the body to integrate 
the implant into the surrounding tissues 
(Bonfield et al., 1980; 1981; Lynn et al., 
2010; Harley et al., 2010a; 2010b; Tanner 
2010a; 2010b). The third rationale relates 
solely to degradable composites, where the 
degradation of the implants, at the 
appropriate rate, allows the gradual 
transfer of load from the implant to the 
natural tissue (Bos et al., 1987).  
When we consider the specific 
requirements for hard tissue replacement 
or augmentation composites, the stiffness 
of the device should be similar to that of 
the bone and no monolithic materials have 
stiffnesses close to those of cortical bone 
and very few close to cancellous bone 
(Currey, 1998). Furthermore, in most cases 
the strength of the device should be higher 
than that of the bone it is replacing or 
augmenting, again a limited number of 
materials fulfil this requirement. Finally, 
the implant should be bioactive to bone, 
thus encouraging bone deposition onto the 
device, bonding it strongly into the 
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surrounding tissue. If the device is also 
degradable then the degradation products 
must be non-toxic and it would be 
beneficial to release products that 
accelerate bone healing (Waris et al., 
1994; Tanner, 2010a; 2010b). 
While these may sound relatively simple 
requirements, when we consider the loads 
on a bone replacement or augmentation 
device, it can be seen that the mechanical 
requirements are high. The loads on a hip 
joint are 3.5 times body weight during 
slow walking, rising to 9 times body 
weight during a stumble (Bergmann et al., 
1983), those on the knee are 2.0 to 2.5 
times body weight during normal activities 
(Mundermann et al., 2008). The peak 
strains on the tibial shaft are 500µε during 
normal walking and are increased during 
running to 1200µε, which assuming the 
Young’s modulus of bone is 
approximately 20GPa equate to 10MPa 
and 24MPa respectively and furthermore 
include a torsional component during the 
push-off phase of the gait cycle (Burr et 
al., 1996). Thus for a typical 80kg person 
the normal loads can be substantial, for 
example 2.0kN on the knee and 2.8kN on 
the hip joint, while for heavy patients the 
forces will be increased proportionally. 
Finally, the fatigue resistance needs to be 
very good, as Wallbridge and Dowson 
(1982) and Goldsmith et al. (2001) found 
that the average number of load cycles 
applied while walking drops from 2 
million per year for someone in their 20s 
down to 0.5 million by the time the subject 
has reached their 80s. They developed 
equations for number of load cycles per 
year (N) versus age of the subject in years 
(A) with able bodied subjects being: 
 N = [3.29 – 0.03A]×106 Eqn (3.1) 
And total hip replacement patients: 
 N = [2.35 – 0.016A] ×106 Eqn (3.2) 
It should be noted that these data sets were 
for people from the UK monitored in the 
late 1990s, while a similar study in 
California at about the same time with 
total joint replacement patients showed 
only about 2/3 of these activity levels 
(Schmalzried et al., 1998). Similar 
numbers of load cycles as seen in the legs 
were predicted for the arms and hands by 
Joyce and Unsworth (2000), although of 
course of lower magnitude.  
When the first version of this chapter was 
written for the 2010 edition of this book 
there were very few bioactive composite 
materials used clinically in bony 
applications. At the time I said “it is 
probably not surprising to see that only a 
few composite materials have been 
reported as being used clinically.” I hope 
that in this new edition the changes that 
have taken place in the first half of the 
2010s are obvious and show that what was 
once a hope is now reality.  
 
3.2 Head and Neck applications 
 
3.2.1 Maxillo-facial applications 
The maxillo-facial region has been the first 
application of many materials due to the 
lower mechanical requirements compared 
to most other skeletal applications. 
However, if there are problems these will 
be more obvious due to the more 
superficial implantation sites and less soft 
tissue covering, as was reported by 
Böstman et al. (1990) and others when 
degradable polylactic acid plates were first 
used clinically.  
The first application of the hydroxyapatite 
(HA) reinforced high density polyethylene 
(HDPE) composite, HAPEX™ developed 
by Bonfield and colleagues (Bonfield et 
al., 1981; Bonfield et al., 1982; Wang et 
al., 1994) was as orbital floor replacement 
device (Downes et al., 1991; Tanner et al., 
1994). Here two different designs were 
developed, the first was a compression 
moulded disk less than 1mm thick and 
approximately 15 mm in diameter which 
was used to close the base of the eye 
socket after fracture of the orbital floor and 
prevent extrusion of the soft tissues into 
the sinus space. The advantages of the 
composite disk were that the strength and 
toughness were such that the devices 
should be cut intra-operatively with either 
a scalpel or a sharp pair of scissors. The 
second device was larger, being a space 
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filling implant for patients who had lost an 
eye. Here the requirement was that the 
implant did not change volume and 
bonded well to the orbital floor. The 
previously used implants were fat pads, 
which could resorb with time leading to 
loss of volume in the orbital cavity, and 
either glass balls or silicone pads, which 
did not bond with the orbital floor and 
therefore could extrude from the socket. In 
both these groups of patients a close bond 
of the HAPEX™ implant to the orbital 
floor could be seen on computed 
tomography (Figure 3.1) and manual 
palpation showed an stable interface. 
However, for commercial reasons, these 
devices were never used beyond the 
original cohort of 18 patients, but 
HAPEX™ progressed to applications in 
middle ear implants discussed later in this 
chapter (section 3.2.2). 
Törmälä and his colleagues at Tampere 
University of Technology in Finland 
developed a series of implants of 
degradable self-reinforced polylactide 
(SR-PLLA) rods, screws and plates 
(Böstmann et al., 1987; Törmälä et al., 
1988; Suuronen et al., 1992; Waris et al., 
1994; Ashammakhi et al., 2001), which 
have been commercialised. The rods and 
screws were manufactured by the 
compression moulding of aligned PLLA 
fibres. The use of the SR-PLLA screws 
was extended to fractures in cancellous 
bone of both the femoral neck and the 
lateral malleous of the fibula and will be 
discussed later. The plates were 
manufactured by extruding the material 
into a plate, these plates were die-drawn 
and the thin sheets were then cut to size 
and moulded together to produce plates 
that were 0.5mm thick and 12 mm by 
40mm in area. These implants were 
initially used in craniofacial surgery 
(Suuronen et al., 
 
 
Figure 3.1 Computed Tomography (CT) scan of the head of a patient 6 months after the 
implantation of a HAPEX™ orbital floor implant showing partial integration of the implant. 
The CT scan shows the lower part of the brain, two orbital sockets, the nasal cavity in the 
centre and the two sinus cavities (darker as they are air filled). The implant is to be seen in 
the right orbital floor (left hand side of the figure) as an additional piece of material with 
similar radiographic density to bone just above the sinus (From Downes et al., 1991). 
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Figure 3.2 showing a) one of the 0.5mm thick self-reinforced PLLA plates used b) to repair 
the bony defects in the skull of a patient suffering from trigonocephaly treated by 
cranioplasty (From Waris et al., 1994). 
 
 
 
1992; Waris et al., 1994; delCampo et al., 
1994), where Suuronen et al. (1992) 
suggest using four of the 0.5mm thick 
plates which are screwed together once 
each plate has been bent into the required 
shape. The individual plates can be bent 
easily, but once the four plates have been 
screwed together they have the required 
stiffness and strength for clinical 
applications. In the study of Waris et al. 
(1994) one to three plates were used 
(Figure 3.2), in children between 6 months 
and 8 years old, so lower loads would be 
expected. Waris et al. suggest that 
ensuring a good covering of “well-
vascularised tissue” and not using an 
excessively large implant will reduce the 
risk of a sterile inflammatory response due 
to the presence of the degrading implant. 
delCampo et al. (1994) used these plates to 
fix osteotomies in the maxilla, that is the 
upper jaw bone, and found good post-
operative stability, without complications. 
Most of the reports have related to the 
craniofacial region (Ashammakhi et al., 
2001), where they have found good 
responses to the implants. An advantage is 
that when used in growing children the 
gradual reduction in the mechanical 
properties as the implant resorbs leads to 
less reduction in the growth of the child’s 
face. They are also able to shape the 
devices intraoperatively by warming the 
implants above their glass transition 
temperature (Tg) of approximately 60˚C. 
However, it should be noted that a self 
reinforced PLLA plates takes about 5 
years to degrade completely compared to 6 
to 12 months for self reinforced 
polyglycolide (PGA) plate (Suuronen et 
al., 1992). 
Zanetti and colleagues (Zanetti et al., 
2001; Zanetti and Nassif, 2003) used a 
hydroxyapatite in polycaprolactone 
composite (Piattelli et al., 1997) which 
was manufactured in the form of flexible 
sheets 0.3 to 1.2mm thick which were used 
to reconstruct both the wall of the outer ear 
canal in 42 patients between the ages of 14 
and 64 (Zanetti et al., 2001) and to repair 
minor defects of the base of the skull in 
seven patients (Zanetti and Nassif, 2003). 
In the ear study, after two years the outer 
ear was successfully reconstructed in 37 
cases (88%) with the outer wall totally re-
epithelialised in 33 cases (79%). There 
was re-occurrence of the clinical problem 
in three patients and in seven patients the 
implants extruded, however compared to 
the results of studies using other implants, 
this was considered to be a successful 
series with three quarters of the patients 
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returning to normal anatomy with no 
remaining infection. In their skull study, 
the defects treated were all less than 30mm 
in diameter and after 18 to 62 months 
follow-up there was no extrusion or 
foreign body reaction. In both studies they 
considered these preliminary results to be 
encouraging. They also comment on the 
ease of cutting and shaping the composite 
implants.  
In Japan Hayashi et al. (2013) used 
degradable plates developed by Shikinami 
and colleagues (Shikinami and Okuno, 
1999; 2001; Shikinami et al., 2005) 
produced by “compression forging” of 
non-sintered hydroxyapatite particles, 3-
5µm in diameter, in poly-L-lactic acid 
(PLLA) and known as F-u-HA/PLLA to 
treat 86 facial fractures in 17 patients. The 
plates were 1mm thick and could be bent 
through 60˚ at room temperature, but for 
further contouring the plates were heated 
to 65-68˚C for 10 to 60 seconds. Follow-
up was for 6-60 months (mean 21.6 
months) with computed tomography pre 
and post-operation and annually thereafter. 
Two plates were involved in 
complications, one patient had excess bone 
formation at a single fracture site, but 
normal healing at their other three 
fractures and another patient developed a 
swelling around one of their three 
implants, due to the development of 
granular tissue. The authors comment that 
the PLLA has gone by 4-5 years and the 
HA particles by 5.5 years. They also 
comment on due to the presence of the HA 
that the radiographic density of the plates 
and the bone are similar, so difficult to 
differentiate on CT scans or radiographs. 
In parallel Landes et al. (2014a; 201b) in 
Frankfurt, Germany used the same plates 
for two different studies. Landes et al. 
(2014a) treated orthognathic surgery 
patients, that is the correction of facial 
deformities, and compared 25 patients 
treated with 120 F-u-HA/PLLA plates with 
25 patients treated with 124 conventional 
titanium alloy plates and followed them up 
for a mean of 22 or 24 months, 
respectively. A large range of clinical 
analyses were performed and no 
substantial differences were seen between 
the two groups. In parallel they treated a 
group of 29 patients with midface or malar 
factures using F-u-HA/PLLA plates and 
screws without a control group (Landes et 
al., 2014b). The rationale for the exclusion 
of a control group was that showing the 
patients their post-operative radiographs 
would immediately display whether they 
had been given composite or metal 
implants, due to the differences in the 
radiographic density. Follow-up was 
performed at 1, 2 and 4 weeks and 1, 3 and 
5 years, by clinicians who had not been 
involved in the original surgery. The 
authors state that “all the patients healed 
well”, but about half failed to attend after 4 
weeks, but said that as they had no 
problems they had not seen the need to 
return. In the patients who did attend at 5 
years, some remaining material was 
present, but without any problems (Figure 
3.3). One patient had further surgery at 28 
months, to correct a scar, and a biopsy was 
taken which showed the surrounding bone 
was in direct contact with the implant 
(Figure 3.4). They conclude that all the 
fractures were successfully stabilised and 
with limited foreign body reactions. More 
recently Sukegama et al. (2016) also 
reported the use of these plates under the 
commercial name OSTEOTRANS MX in 
35 patients. All patients healed their 
fractures “satisfactorially” with three 
complications, two due to plate exposure 
and one where the patient complained of 
discomfort, all these plates were removed 
at times between 4 and 12 months and 
examined. Scanning electron microscopy 
showed direct bone contact with all three 
of these plates, the molecular weight of 
both the plates and the screws decreased 
between 4 and 8 or 12 months. 
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a)  
b)  
 
Figure 3.3 a) F-u-HA/PLLA plates and screws implanted in a 56 year old male with a sports 
injury and b) reconstructed CT scan at 53 months post surgery showing the integration of the 
implants into the bone (from Landes et al., 2014b). 
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Figure 3.4 A F-u-HA/PLLA plate and screw after 28 months implantation showing direct 
contact between bone (Knochen) and the plate (Polymer). Heidenhain azan stain, original 
magnification ×400 (from Landes et al., 2014b). 
 
Aitasalo et al. (2016) from Turku, Finland 
developed a non-degradable bilayer 
composite skull defect implant, based on 
an outer layer of woven E glass fibres in a 
bisphenol-a-glycidyl methacrylate and 
triethyleneglycoldimethacrylate 
(pBisGMA-pTEGDMA) acrylic co-
polymer with bioglass particles providing 
a porous inner layer. Each device was 
designed using CT data and rapid 
prototyping to produce a model for the 
implant. Then the woven glass fibre 
composite was hand laid down to provide 
control of the fibre orientation and to give 
an approximately 1.1mm thick, relatively 
smooth, outer layer with high strength that 
overlapped the defect by 6 to 8mm all 
round. Below this outer layer was a 
typically 3.5mm thickness porous layer 
containing bioglass particles and filling 
into the actual defect. The monomers were 
cured with visible light followed by heat 
and then the device was sterilized using 
hydrogen peroxide. They report the results 
from 12 adult patients, from 26 to 78 years 
old, with large skull defects followed up 
for between six months and four years 
(Figure 3.5). All implants remained in 
position and no patients showed 
inflammatory or toxic responses. Also in 
Turku Piitulainen et al. (2015) implanted 
the same design in skull defects in seven 
children between the ages of 2.5 and 16 
years, mainly after skull fractures. 
Interestingly, they comment that the 
porosity of the inner layer of the device 
encourages blood to be absorbed when 
implanted. Follow-up was for 14 to 53 
months, there were some complications, 
including two infections at the surgical site 
and leak of the cerebrospinal fluid, but at 
no higher a level than other studies of 
similar patient cohorts. They conclude that 
the implants were safe, but longer follow-
up and more patients are needed for 
definitive conclusions on the biomaterial.  
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a)  b)  
Figure 3.5 a) internal view of a and b) the CT scans per-operatively and at 9 months post 
operation (from Aitasalo et al., 2014) 
 
An application in sinus repair of a 
composite of collagen reinforced with 
anorganic bovine bone, that is after 
removal of the protein phase, has been 
reported by Alayan et al. (2016). They 
compared the composite with a mixture of 
anorganic bovine bone and autogenous 
bone. The anorganic bovine bone was used 
as granules with the aim of encouraging 
vascular ingrowth and was the 
commercially available Bio-Oss® granules 
combined with an equal volume of 
autogenous bone, while the second implant 
studied was blocks of anorganic bovine 
bone had 10% porcine type I collagen 
added, known as Bio-Oss Collagen®. 
There were twenty patients were in each 
group and after 5 months they were given 
an implant at the operation site and at this 
time a histological section was taken. 
Undemineralised histology showed very 
few differences in the response to the two 
materials, both showed good bone 
ingrowth and the authors considered that 
either material could be used in this 
application. 
Another hydroxyapatite-collagen 
composite was prepared in theatre by 
D’Agostino et al. (2016) and used to 
reshape the zygomatic bone (also called 
the malar bone or the cheek bone) in 430 
patients. After mixing the composite of 
HA granules with collagen microfibrils 
and sterile saline under sterile conditions 
and shaping, it was heated using a 150W 
lamp for at least 2.5 hours to stiffen the 
material before implantation into pockets 
formed in the periosteum. Follow-up was 3 
to 10 years and all patients were 
radiographed to check position and 
integration of the implants. Smaller groups 
underwent more extensive analysis, 110 
patients had cone beam tomography after 
at least 36 months, 76 patients used a 
visual analogue scale to evaluate their 
view of the restoration of their face shape 
and 8 patients who subsequently had a 
screw removed agreed to core biopsies for 
histological analysis. The complication 
rate was 1.56%, mainly malpositioning of 
the implant or resorption of the implant. At 
6 months the composite graft was still 
visible as granules, but without migration 
and by 24 months the granular structure 
was less obvious and becoming 
incorporated into the supporting bone. 
Histologically, 70% of patients had new 
bone formation and immunohistochemistry 
showed osteoclastic activity on the 
granules.  
Thus a range of bioactive composites, 
many biodegradable, have been introduced 
recently for maxilla-facial surgery and 
have been at least as successful as early 
devices in these low load bearing 
applications.  
 
3.2.2 Aural applications 
The clinical success of the HAPEX™ 
orbital implants encouraged Smith & 
Nephew ENT to use HAPEX™ in middle 
ear implants in the 1990s. At the time they 
were producing a range of middle ear 
implants, such as those designed by 
Goldenberg (1994) and Dornhoffer (1998), 
with hydroxyapatite heads that contacted 
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the tympanic membrane (ear drum) and 
had ultrahigh molecular weight 
polyethylene (UHMWPE) shafts.  These 
shafts were cut intra operatively to the 
required length to fit on the staples, the last 
bone of the train of three bones that 
transmit and amplify sound vibrations 
from the outer ear to the inner ear. 
Hydroxyapatite was used for contact with 
the tympanic membrane as other materials 
are extruded out of the ear, while the 
UHMWPE was used as it could be cut 
easily in the operating theatre to enable the 
implant to be tailored to fit the patient. 
HAPEX™ was used to replace the 
UHMWPE as there was considered to be 
increased possibility of the stapes bonding 
with an HAPEX™ shaft, increasing the 
long term stability of the implant, the 
presence of the HA particles in the 
polyethylene made the material easier to 
trim intra operatively and finally the 
increased density of HAPEX™ compared 
with UHMWPE should increase the 
transfer of sound through the shaft and 
thus improve the patients hearing. 
Goldenberg and Driver (2000) in the US 
considered the clinical success of these 
implants, reviewing the results for 233 
patients of whom 77 had their implants in 
situ for more than 5 years. Overall, the 
hearing success rate was 56.8% with 
implant extrusion occurring in 5.3% and 
visible slippage of the implant in 7.7% of 
patients. They concluded that the implant 
provided good hearing which was stable 
with time and that the extrusion rate was 
low. Meijer et al. (2002) in The 
Netherlands reviewed the histological 
response to 11 of these HAPEX™ 
implants which were retrieved 2 to 20 
months after implantation due to re-
occurrence of the original clinical 
problems. They found a fibrous tissue 
layer covering all the implants (Figure 3.6) 
but, in no cases did they find a foreign 
body response, which they comment is in 
contrast to similar implants manufactured 
using Proplast® or Plastipore® used in the 
middle ear. More recently Hahn and 
Bojrab (2013) in Michigan, USA, 
compared the clinical results of 46 patients 
who had been treated with HAPEX™ 
implants with 176 patients where again the 
implant head was hydroxyapatite but the 
shaft was titanium with an adjustable 
length. For the HAPEX™ implants the 
mean follow-up was 42.9 months 
compared with 28.9 months for the 
titanium shaft implant in patient groups 
with mean ages of 36.3 and 36.2, 
respectively. The clinical results were 
similar with the air-bone gap dropping 
from 33.2 to 14.0 dB in the HAPEX™ 
implants and 34.0 to 14.7 with the titanium 
stem, similarly a “successful outcome”, 
that is an air-bone gap of less than 20 dB, 
was seen in 80.4 and 81.3% patients, 
respectively. For commercial reasons these 
devices are no longer available. 
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Figure 3.6 Scanning electron microscopic appearance of a HAPEX™ middle ear prosthesis 
consisting of a hydroxylapatite head (H) and a hydroxylapatite-polyethylene shaft (S). The 
shaft has been trimmed intra-operatively to fit to the appropriate size in the middle ear. The 
shaft is composed of sintered hydroxylapatite and polyethylene which gives a smooth but 
irregular surface (From Meijer et al., 2002). 
 
3.2.3 Dental Applications 
As with many other activities in the field 
of biomaterials, dental applications have 
lead the surgical applications of 
biomaterials. The major dental use of 
biocomposites, that is as tooth filling 
materials to replace dental amalgam, will 
not be considered in this chapter. 
However, implantable composites have 
been used as posts for tooth replacement to 
provide support for either natural or 
artificial teeth or on the tongue side of 
teeth to support, either temporarily or 
permanently a tooth where the anchorage 
has been weakened (Chan et al., 2006).  
While the Brånemark titanium tooth root 
replacement and similar designs are now 
used almost exclusively, in the past 
composites have been used to treat such 
problems. Hodosh et al. (1976) 
manufactured their own implants by 
mixing polymethylmethacrylate (PMMA) 
with vitreous carbon (VC). After 
extraction of one or more teeth, they 
produced moulds of the gaps in their 
patients’ alveolar ridges and filled these 
moulds with a mixture of 95% PMMA and 
5% VC, presumably these are weight 
percentages although this is not stated, 
with MMA monomer and then heat 
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polymerised. The implants were sand 
blasted to remove the surface layer and 
expose the VC. After ultrasound cleaning 
and sterilisation these were implanted into 
their patients and used to provide supports 
for fixed partial dentures. The authors say 
that they obtained rapid healing with 
minimal discomfort, which seems 
surprising given their statement that the 
composite “is a mildly irritating, strong 
implant material”. In their study of 15 
patients also found minimal bone loss with 
retention of the alveolar ridge height. They 
do comment that the use of a material with 
lower modulus than bone produces better 
load transfer from the implant to the 
supporting bone.  
Kawai et al. (2014) have used a collagen-
calcium phosphate composite developed 
by Kamakura et al. (2006), although in this 
case the calcium phosphate is octocalcium 
phosphate (Ca8H2(PO4)6.5H2O) combined 
with porcine skin origin collagen, thus 
presumably a mixture of Type I and Type 
III collagen. Their first study (Kawai et al., 
2014) looked at two patients with radicular 
cysts (defects at the base of incisor teeth) 
of 8mm diameter and 5×5×10mm 
respectively and these healed well with 
some bone formation visible in the graft 
from 3 months and increased bone 
formation by 6 months. Thereafter they 
(Kawai et al. 2016) extended the study to 
give a total of 10 patients, who either had 
similar cysts (5) or had impacted teeth 
extracted (5). The defects were filled with 
their composite material in the form of 
discs 9mm diameter and 1 mm thick prior 
drying and sterilisation, although the size 
of the final implants is not given. As many 
discs as could be fitted, were implanted in 
each defect to fill the space, resulting in 4-
22 discs used per patient. There were two 
minor complications, one case of material 
extrusion and pus discharge in a patient 
with a radicular cyst and the excess 
material was removed and the area washed 
daily with local antibiotics for the next 5 
days, the other patient had a tooth 
extracted and there was “insufficient 
closure of the wound” and again local 
washing with an antibiotic wash and the 
wound healed. CT scans at 3, 6 and 12 
months showed an increases in 
radiographic density to 3 and then 6 
months, but the density then levelled off 
between 6 and 12 months. Haematology 
and biochemical studies performed at 1 
day, 1 week, 1, 3, 6, 9 and 12 months post 
operation showed nothing remarkable 
beyond an increase in the white blood cell 
count at 1 day which had dropped to 
normal levels by 7 days.  
 
3.3 Axial skeleton applications 
 
3.3.1 Internal applications 
The first composite device to reach axial 
skeletal clinical application was a carbon 
fibre in epoxy resin composite fracture 
fixation plate developed by Hastings and 
colleagues (Hastings, 1978; Bradley et al., 
1980; Ali et al., 1990) where carbon fibres 
were used to reinforce epoxy resin. The 
devices were manufactured by a 
combination of heat and pressure applied 
to 21 layers of carbon fibres in epoxy pre-
preg with fibre directions along and at 45˚ 
to the long axis of the plates. Once the 
plates were manufactured screw holes 
were drilled and countersunk with the size 
and shape of the implant being identical to 
a typical metal fracture fixation plate of 
that time. These plates had a bending 
stiffness approximately one quarter that of 
the equivalent metal plates, yet the both 
fatigue limit and angulation at failure were 
60% higher. The biocompatibility was 
assessed by in vivo implantation in mice 
both in bone and with muscle contact. 
These plates were used in 40 forearm 
fractures in 29 patients (Ali et al., 1990). 
The application was limited to the forearm 
as these plates could not be bent to fir the 
patient needed for application elsewhere in 
the body, unlike metal implants. Clinically 
the patients used their arms earlier than 
those treated with equivalent metal 
implants and in 70% of the cases the 
healing process was secondary healing 
with callus formation (Figure 3.7) rather 
than primary healing with minimal callus 
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formation, that was considered desirable at 
that time for internally fixed fractures. 
Primary healing occurs where the motion 
at the fracture site is less than 
approximately 100µm, whereas secondary 
healing occurs with limited motion at the 
fracture site and is a substantially faster 
process. All the implants were removed 
after healing was complete. Histological 
analysis showed minimal response in all 
but 6 fractures, although some carbon 
particles were found in the soft tissue 
surrounding the implant. In the other cases 
the responses were minor, except in two 
patients and in one of these, the implant 
was found to be infected. As a result of the 
histological studies the authors suggest 
that there was no reason to remove the 
implants in future studies. The limit on the 
use of these devices was their inability to 
be bent to fit the patient, thus limiting their 
use to the forearm and this constraint 
resulted in them being discontinued. 
However, thermoplastic and thermoset 
polymer matrices reinforced by carbon and 
glass fibers have been used to produce 
composite hip joint prostheses as discussed 
elsewhere in this book. 
 
More recently the self reinforced poly-L-
lactide (SR-PLLA) materials developed by 
Törmälä and his colleagues (Böstmann et 
al., 1987; Törmälä et al., 1988; Suuronen 
et al., 1992; Waris et al., 1994; 
Ashammakhi et al., 2001) have been used 
in internal fixation of the ankle and in 
femoral neck fractures. In an early study of 
displaced medial and lateral malleolar 
fractures (Böstman et al., 1987) they 
compared the results of treatment with 
cylinders of self-reinforced polylactide-
glycolide (SR-PLGA) fibres with 
conventional metal screws. They found no 
differences in the anatomical and 
functional results with similar levels of 
complications in each group. In a later 
study also in the ankle, Joukainen et al. 
(2007) compared screws manufactured of 
self reinforced polylactide with 70%L and 
30%LD (SR-PLA70) with those made 
from 100% L PLA (SR-PLLA) for the 
treatment of ankle fractures in 62 patients. 
There was minimal difference in the 
mechanical properties of the two devices, 
but the co-polymer reduced the time that 
the implants kept their strength in vitro 
from 36 weeks to 24 weeks. They found 
that the patients with the co-polymer 
implants (SR-PLA70) had 65 days sick 
leave compared with 60 days for the SR-
PLLA treated patients, but no other 
statistically significant differences. In both
 
 
 
Figure 3.7 Clinical response to the carbon fibre reinforced epoxy resin fracture fixation plates 
used by Ali et al. (1990) in the forearm showing the “healing by close-knit callus which was 
seen in 70% of cases” (From Ali et al., 1990). 
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Figure 3.8 Fracture of lateral malleolus preoperatively (a,b) and at the 1-year follow-up (c,d) 
treated with two SR-PLA70 screws. Note the syndesmotic ossification between the tibia and 
the fibular. The patient did not report any problems at the 1-year follow-up (From Joukainen 
et al., 2007). 
 
groups the screw track was still visible at 
one year (Figure 3.8). In the femoral neck 
study Jukkala-Partio et al. (2000) treated 
40 patients with subcapital fractures using 
three 6.3mm diameter SR-PLLA screws 
per fracture and the results were compared 
with 38 patients treated with 3 metal 
screws each 7.0mm in diameter. The 
groups were similar in age and clinical 
problems and there were similar numbers 
of re-dislocations in each group, however 
the ability to walk and long term range of 
movement were greater in the patients 
treated with the degradable implant. 
In joint replacement Field and Rushton 
(Field and Rushton, 2005; Field et al., 
2006) developed the Cambridge Cup to 
replace the horseshoe of articular cartilage 
in the acetabulum in patients under going 
what would normally be a 
hemiarthoplasty, that is replacement of the 
femoral head only, after femoral neck 
fractures, in elderly, low activity, 
osteoporotic patients. In these patients a 
large femoral head articulates with the 
articular cartilage and with time the 
cartilage can wear through, however many 
of these patients are not well enough in 
themselves to be suitable for a total hip 
replacement. The Cambridge cup consists 
of 3mm of UHMWPE supported by a 
1.5mm thick layer carbon fibre reinforced 
polybutylenetere-phthalate (PBT) or in a 
later design polyetheretherketone (PEEK). 
Implant fixation was either a 60µm thick 
of plasma sprayed HA coating or PMMA 
bone cement supplemented with some 
composite fixation pins (Figure 3.9). The 
concept of this design is that the implant 
stiffness is similar to that of the articular 
cartilage and subchondral bone plate 
structure that it is replacing. Compared to 
other studies using composite materials 
this was a much older age group of 
patients from 70 to 100 years with a mean 
age of 81.8 years, however this age range 
did mean that post mortem studies have 
been performed. They found that despite 
the relatively thin layer of UHMWPE 
there was no significant wear, which they 
attributed to the flexibility of the device. 
The PMMA implanted prostheses 
migrated more than those relying on the 
HA coating for fixation, which would 
normally be considered an indictor of 
increased long term risk of implant 
loosening (Ryd, 1985). Dual Energy X-ray 
Absorptiometry (DEXA) of the bone 
surrounding and supporting the implant 
showed that the bone density dropped in 
the first 6 to 12 months, but then returned 
to post operative levels. Brooks et al. 
(2010) performed post-mortem 
histological analysis of 12 of these cups, 
retrieved 2 to 84 months post implanation, 
from an initial group of 50 women. These 
post mortem studies showed more bone 
contact with the HA coated implants, even 
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Figure 3.9 Cambridge Cup showing the outer polybutyleneterephthalate (PBT) carbon fibre 
composite shell with the inner UHMWPE bearing and holes for the insertion of fixation pegs 
(From Field and Rushton, 2005). 
 
after resorption of the HA coating, than the 
non-coated implants where fibrous 
encapsulation was seen. They further note 
that the flexible component produced by 
the combination of the PE lining and the 
composite backing did not reduce stability 
of the implant or lead to excessive wear. 
The treatment of bony defects has been 
considered by various groups. The 
requirement is to provide a scaffold in 
contact over which osteoblasts can travel 
and deposit new bone, thus working on the 
principle of osteoconduction, with the 
scaffold eventually removed by 
osteoclasts. Many clinicians use 
hydroxyapatite or other calcium 
phosphates as granules or as porous blocks 
and these will not be considered here. A 
few groups have investigated composite 
implant materials, an example is Sotome et 
al. (2016) who compared HA/collagen 
(Refit®) with β-tricalcium phosphate (β-
TCP, Osferion®) to fill medium, but above 
the critical size defects (less than 30cm3) 
in two groups each of 63 patients, with 
patients allocated by a computer program 
to produce equivalent groups. Follow-up 
was using radiographs at various times 
between 2 and 24 weeks, each radiograph 
was assessed by three orthopaedic 
surgeons, however, due to the differences 
in the radiographic density of the two 
implants, they could not be blinded. Each 
defect was scored between 0 and 2 for 
both the marginal zone to describe the 
degree of integration where 0 was a 
complete radiolucent line and 2 was no 
line visible, while bone regeneration was 0 
for no bone regeneration and 2 was 
complete replacement by new bone, thus 
“highly effective” was a total of 4 
dropping down to “ineffective” for 0 or 1 
total. They comment that once wetted the 
HA/collagen composite was “elastic”. By 
18 weeks statistically more of the 
HA/collagen treated patients were classed 
as having highly effective healing than 
those with the β-TCP implants. 
Treating osteochondral defects, that is 
defects affecting both the articular 
cartilage and the underlying bone, is seen 
as a treatment for patients with early 
localised osteoarthritis, rather than leaving 
until the problem is serious enough to 
require total joint replacement. This 
treatment has particularly concentrated on 
the knee and ankle problems. 
Mosiacplasty, that is implanting plugs of 
 17 
cartilage and underlying subchondral and 
cancellous bone from the non-load bearing 
edges of a joint into the defect has been 
tried (Cognault et al., 2015), but has the 
usual limitations of autografts of a limited 
supply of donor tissue, thus various groups 
have tried to develop an artificial 
equivalent. FinCermica in Faenza, Italy 
have commercialised one implant, 
Maioregen®, based on the work of 
Tampieri et al. (2003). It is described as 
three layered implant where the outermost 
layer, to replace the cartilage, is of smooth 
surfaced type I collagen, the second layer 
replacing the tide-layer in the cartilage is 
60% type I collagen and 40% 
hydroxyapatite and the deep, cancellous 
bone contacting, layer is 30% type I 
collagen and 70% hydroxyapatite (Kon et 
al., 2009). Although whether the collagen-
hydroxyapatite contents are described by 
weight or volume is not defined, but based 
on the data from Tampieri et al. (2003) it 
is probably by weight. Given the nearly a 
factor of three difference in densities 
between these two phases this will make a 
substantial difference in the actual 
amounts of the two phases present. All 
layers are porous and the collagen-
hydroxyapatite composite is described as 
nanostructured and the hydroxyapatite is 
non-stoichiometric, but self assembled into 
the collagen. Kon et al. (2009) report a 
single 46 year old patient with 4 individual 
defects in one knee treated. By a year post 
surgery he was back playing tennis with 
only minimal oedema present on MRI 
scans. The same group (Kon et al. 2014) 
report on 11 patients with a total of 13 
defects in their tibial plateaux, up to 
12.5cm2 in area. The patients’ knee scores 
increased at one year and remained at that 
level at 2 years, and of these patients eight 
considered that they had a marked 
improvement, two had moderate 
improvements and one considered that 
they were slightly worse at 2 years. The 
authors considered the results to be 
“promising” for an initial study.  In 
contrast, Brix et al. (2016) using the same 
implants treated 8 patients between the 
ages of 15 and 51. While the clinical 
scores increased, MR imaging showed 
good integration at the cancellous bone 
level, but limited integration of the 
cartilage, a known problem with 
attempting to repair cartilage defects. 
More recently Christensen et al. (2016) 
using the same device in 10 patients 
followed for 3 years in a prospective 
study, two patients has their implants 
removed at 6 days and 3 months post 
surgery due to swelling of their knees, two 
more patients had long term swelling 
leaving 6 patients for MRI studies of their 
knees at 1 and 2.5 years post-operation and 
unlike other studies they performed CT 
(computed tomography). The CT analysis 
found limited subchondral bone ingrowth 
into the lowest layer of the device and 
limited cartilage repair between the 
implant and the native surrounding tissue. 
They did find significant and substantial 
improvements in the pain, sporting activity 
and Quality of Life score, but still stopped 
the study and suggest that the this implant 
“should be used with caution” despite the 
good results seen by other groups.  
A similar concept osteochondral defect 
implant, commercially known as 
ChondroMimetic™, was produced by a 
combined Cambridge-MIT group (Lynn et 
al., 2010; Harley et al., 2010a; 2010b), but 
with only two layers. The outer, articular 
cartilage replacing, layer is a composite of 
type II collagen and glycosaminoglycan 
(GAG), while the inner cancellous bone 
contacting layer is produced by co-
precipitation of collagen type I, 
glycosaminoglycans and calcium into 
phosphoric acid to produce a calcium 
phosphate reinforced collagen composite 
and then freeze drying to produce porosity. 
The calcium and phosphoric acid produced 
octocalcium phosphate, which was then 
hydrolytically transformed into HA. Cross 
linking was performed chemically using a 
solution of 1-ethyl-3-(3-
dimethylaminopropyl) carboniimide and 
N-hydroxysuccinimde in water. The two 
layers were joined by pouring the type I 
collagen-GAG-HA composite into a 
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mould, followed the type II collagen-GAG 
composite and allowing the two materials 
to diffuse into each other for 30 minutes at 
room temperature, prior to freeze drying. 
Controlling the freezing rate and final 
temperature produced interconnected pores 
and allowed control of the pore size 
between 56µm and 1085µm. While the 
clinical results have been reported in a 
conference abstract, they have not as yet 
been published.  
 
3.3.2 External applications 
The principal applications of composites 
external to the body are in fracture 
fixation. Two major applications are in 
use; fibre reinforced composites as 
external casts and carbon fibre reinforced 
epoxy rings used in the Ilizarov External 
Fixator.  
Plaster of Paris has many disadvantages 
being fairly radiopaque, mechanically 
brittle, of fairly high density and not being 
water resistant. Various orthopaedic 
companies have developed a wide woven 
fibre mesh impregnated with a settable 
polymer as a plaster of Paris replacement. 
The requirements are low radiopacity to 
allow the process of fracture healing to be 
followed radiographically without the need 
to remove the cast, higher failure 
properties, water resistance and lower 
density. The polymer setting initially was 
by heat, however the more recent 
formulations are light settable. After a few 
initial problems with the heat setting 
formulations in the developed world 
plaster of Paris casts have been almost 
completely replaced with composite 
materials.  
The Ilizarov external fixator was 
developed by Gavriil Ilizarov in Siberia in 
the 1950s, however it was only the 1980s 
that this external fixator became known in 
the West (Ilizarov, 1988). The fixator is 
used for fracture fixation, in limb 
lengthening and limb straightening. It 
consists of a series of thin wires, 1.5 or 
1.8mm in diameter, that pass through the 
bone above and below the fracture or 
osteotomy, these wires are then tensioned 
onto a series of rings that are connected to 
form a scaffolding system around the 
injured limb. For limb correction, the rings 
are gradually moved using the connectors 
that cross the osteotomy site to move the 
bones to their required anatomy. Initially 
the entire fixator was fabricated of 
stainless steel, which made a heavy system 
with large amounts of radiopaque metal, 
potentially making imaging the fracture 
difficult. However, random chopped 
carbon fibre in epoxy resin and knitted 
Kevlar-29 in epoxy rings for the Ilizarov 
have been developed (Baidya et al., 2001 a 
& b). These rings were extensively tested 
both as individual structures and as parts 
of external fixators. They found that the 
composite rings were less stiff than the 
steel rings, but had sufficient stiffness and 
strength to be used clinically, while the 
reduced weight and radiopacity has 
benefits to both patients and surgeons.  
 
3.4 Advantages in the use of composites 
for hard tissue applications 
Composites can be produced that have 
similar stiffness to the natural tissues they 
are replacing. This modulus matching can 
lead to better biological responses in the 
form of reducing stress shielding below 
the devices or stress concentrations at the 
ends of the implant. Furthermore many of 
these newer composites contain one or 
more calcium phosphates, which are 
released from the implant providing a 
supply of calcium and phosphate ions, or 
other biologically active moieties, that can 
be incorporated into the bone and 
accelerating the healing process. 
Composites implants can be tailored in the 
operating theatre to fit the patient, unlike 
most metal implants, which can only be 
bent but not cut, or all ceramic implants, 
which are difficult to cut and cannot be 
bent. However, the methods of shaping 
composites intraoperatively are different 
from those used with metal implants 
requiring heat or cutting rather than plastic 
deformation of the metal.  
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3.5 Disadvantages in the use of 
composites for hard tissue applications 
 
As yet most of the composites which have 
been implanted have been limited to lower 
load bearing applications due to their poor 
strength and fracture toughness. Some of 
the less successful applications have been 
where the metal implant design has been 
exactly reproduced in a composite rather 
than start with the implant requirements 
and use the properties of the composite to 
drive the design, that is design based on 
the properties of the composite to be used.  
 
3.6 Future trends 
Composites have been used in patients 
since the 1970s. However the early 
composites were carbon containing and 
produced only acceptable biological 
responses. The newer variations of 
composites are bioactive producing 
beneficial or active biological responses. 
One of the major developments has been 
the selection of either non-degradable or 
degradable polymers as the basis of 
composites depending on the clinical 
application. In joint replacement and 
similar applications non-degradable 
implants are required, while for fracture 
fixation, and even more so for tissue 
engineering scaffolds, degradable 
scaffolds will allow the patient to be 
treated and then forget that they ever had 
an artificial material implanted. It seems 
likely that the implant material and design 
will be based on the best combination for 
the specific clinical problem rather than 
treating the clinical problem with an 
available implant. 
It is interesting to note that there have only 
been a limited number of composites 
which have progressed through to 
published clinical trials, however 
considering how long it takes to progress 
from development of a new material to 
clinical use we should expect an increasing 
number of composites, such as those 
discussed elsewhere in this book, to enter 
clinical use in the next five to ten years. 
With time our understanding of the 
advantages and disadvantages of the 
clinical use of composites is increasing 
which should accelerate the introduction of 
further more advanced composites be they 
bioactive materials or Smart materials.  
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